文献速递乳腺癌放疗姑息放疗与转移瘤

在寡转移性乳腺癌的标准全身治疗中加入转移灶导向治疗(EXTEND):一项多中心、随机2期试验

Adding Metastasis-Directed Therapy to Standard-of-Care Systemic Therapy for Oligometastatic Breast Cancer (EXTEND): A Multicenter, Randomized Phase 2 Trial.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2024-10-30

这项多中心随机2期篮式试验将≤5个转移灶的寡转移性乳腺癌患者1:1随机分配至转移灶导向治疗(MDT)联合标准全身治疗组或单纯标准全身治疗组,主要终点为无进展生存期(PFS)。中位随访24.8个月,MDT组中位PFS 15.6个月 vs 无MDT组24.9个月(HR 0.91,95%CI 0.34-2.48,P=0.86),总生存期、至后续全身治疗时间、至新转移灶出现时间及生活质量等均无显著差异。作者结论认为在未筛选的寡转移性乳腺癌患者中,标准全身治疗基础上加用MDT未改善PFS,提示MDT可能无全身获益。

要点

  • MDT联合标准全身治疗未改善寡转移性乳腺癌的PFS(HR 0.91,95%CI 0.34-2.48,P=0.86)。
  • 总生存期、至后续全身治疗时间及至新转移灶出现时间均无显著差异(均P>0.05)。
  • 生活质量、系统性T细胞活化及T细胞刺激性细胞因子浓度均无显著差异。

核心结论

  • 在寡转移性乳腺癌患者中,标准全身治疗基础上加用MDT未改善PFS。
  • 这些发现提示MDT在otherwise unselected的寡转移性乳腺癌患者中可能无全身获益,但该试验受限于异质性小样本及两个治疗组表现均超出预期。

研究设计与样本

  • EXTEND为多中心2期随机篮式试验(NCT03599765),纳入≤5个转移灶的患者,1:1随机分配至MDT(对所有病灶行根治性局部治疗联合标准全身治疗)或单纯标准全身治疗。
  • 2018年9月至2022年7月,MDT组22例、无MDT组21例被随机分配。
  • 主要终点为PFS,次要终点包括总生存期、至后续全身治疗时间及至新转移灶出现时间,探索性分析包括生活质量与系统性免疫应答指标。

主要发现

  • 中位随访24.8个月,MDT组中位PFS 15.6个月 vs 无MDT组24.9个月(HR 0.91,95%CI 0.34-2.48,P=0.86)。
  • MDT未改善总生存期、至后续全身治疗时间或至新转移灶出现时间(均P>0.05)。
  • 生活质量指标、系统性T细胞活化及T细胞刺激性细胞因子浓度均无显著差异。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 该试验受限于异质性小样本。
  • 该试验受限于两个治疗组表现均超出预期。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Prior evidence suggests a progression-free survival (PFS) benefit from adding metastasis-directed therapy (MDT) to standard-of-care (SOC) systemic therapy for patients with some oligometastatic solid tumors. Randomized trials testing this hypothesis in breast cancer have yet to be published. We sought to determine whether adding MDT to SOC systemic therapy improves PFS in oligometastatic breast cancer. METHODS AND MATERIALS: External Beam Radiation to Eliminate Nominal Metastatic Disease is a multicenter phase 2 randomized basket trial testing the addition of MDT to SOC systemic therapy in patients with ≤5 metastases (NCT03599765). Patients were randomly assigned 1:1 to MDT (definitive local treatment to all sites of disease, plus SOC systemic therapy) or to SOC systemic therapy-only. Primary endpoint was PFS, and secondary endpoints included overall survival, time to subsequent line of systemic therapy, and time to the appearance of new metastases. Exploratory analyses included quality of life and systemic immune response measures. RESULTS: From September 2018 through July 2022, 22 and 21 patients were randomly assigned to the MDT and no-MDT arms, respectively. At a median follow-up of 24.8 months, PFS was not improved with the addition of MDT to SOC systemic therapy (median PFS 15.6 months MDT vs 24.9 months no-MDT [hazard ratio, 0.91; 95% CI, 0.34-2.48; P = .86]). Similarly, MDT did not improve overall survival, time to subsequent line of systemic therapy, or time to the appearance of new metastases (all P > .05). No significant differences were found in quality of life measures, systemic T-cell activation, or T-cell stimulatory cytokine concentration. CONCLUSIONS: Among patients with oligometastatic breast cancer, the addition of MDT to SOC systemic therapy did not improve PFS. These findings suggest that MDT may have no systemic benefit in otherwise unselected patients with oligometastatic breast cancer, although this trial was limited by a heterogeneous and small sample size and overperformance of both treatment arms.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Reddy JP, Sherry AD, Fellman B, et al. Adding Metastasis-Directed Therapy to Standard-of-Care Systemic Therapy for Oligometastatic Breast Cancer (EXTEND): A Multicenter, Randomized Phase 2 Trial. Int J Radiat Oncol Biol Phys. 2024. PMID: 39486645. doi:10.1016/j.ijrobp.2024.10.030

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。